Shots:
- The P-III (EMERALD-3) trial assessed single priming dose of Imjudo (300mg) + Imfinzi (1500mg) followed by Imfinzi (Q4W) + transarterial chemoembolisation (TACE) ± lenvatinib vs TACE alone in 760 pts unresectable HCC eligible for embolization
- Imjudo + Imfinzi + Lenvatinib & TACE showed improved PFS (1EP) vs TACE alone, with OS (2EP) demonstrating a favorable trend in the interim analysis
- Also, Single Imjudo regular interval Imfinzi regimen + TACE showed trends toward improved PFS & OS vs TACE alone, while OS & other key 2EPs will be evaluated further; data will be presented at a future meeting & shared with global regulatory authorities
Ref: AstraZeneca | Image: AstraZeneca | Press Release
Related News: AstraZeneca Reports the P-III (OBERON & TITANIA) Trial Data on Tozorakimab for Chronic Obstructive Pulmonary Disease (COPD)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
